Skip to main content
SpringerLink
Log in

Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a)

  • Chapter
  • First Online:
S3-Leitlinie Schizophrenie

  • 3916 Accesses

Zusammenfassung

In diesem Kapitel erfolgt die Darstellung der allgemeinen und spezifischen Pharmakotherapie, sowie weiterer somatischer Behandlungsverfahren für die Therapie von Menschen mit einer Schizophrenie. Weiterhin werden die Nebenwirkungen einer antipsychotischen Behandlung sowie deren Diagnostik und Therapie dargestellt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. DGPPN (2006) S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 – Behandlungsleitlinie Schizophrenie. Gaebel Wf, Falkai, P., Weinmann, S., Wobrock T., editor. Steinkopff, Darmstadt

    Google Scholar 

  2. DGPPN (2015) S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depressionen – Langfassung, 2. Aufl. 2015 Version 3

    Google Scholar 

  3. NICE (2014) NICE clinical guideline 178 – psychosis and schizophrenia in adults: treatment and management – issued: February 2014 last modified: March 2014. guidance.nice.org.uk/cg178

  4. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull 35(3):549–562

    Article  PubMed  PubMed Central  Google Scholar 

  5. Haase HK (1961) Das therapeutische Achsensyndrom neuroleptischer Medikamente und seine Beziehungen zu extrapyramidaler Symptomatik. Fortschr Neurol Psychiatr 29:245–268

    CAS  Google Scholar 

  6. Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika. Pharmacopsychiatry 4(4):182–191

    Article  CAS  Google Scholar 

  7. Grunder G, Hippius H, Carlsson A (2009) The ‚atypicality‘ of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 8(3):197–202

    Article  CAS  PubMed  Google Scholar 

  8. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45(9):789–796

    Article  CAS  PubMed  Google Scholar 

  9. Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24(1):62–67

    CAS  PubMed  Google Scholar 

  10. Müller MJ, Benkert O (2017) Antipsychotika. In: Benkert O, Hippius H (Hrsg) Kompendium der Psychiatrischen Pharmakotherapie, Bd 11. Springer, Berlin/Heidelberg, S 269–488

    Chapter  Google Scholar 

  11. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962

    Article  CAS  PubMed  Google Scholar 

  12. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14(4):429–447

    Article  CAS  PubMed  Google Scholar 

  13. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC (2010) Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 67(3):255–262

    Article  CAS  PubMed  Google Scholar 

  14. Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64(6):663–667

    Article  CAS  PubMed  Google Scholar 

  15. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2):314–326

    Article  PubMed  PubMed Central  Google Scholar 

  16. Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, Geddes J, Davis JM (2015) Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 41(6):1397–1402

    Article  PubMed  PubMed Central  Google Scholar 

  17. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM (2012) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 5:CD008016

    Google Scholar 

  18. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379(9831):2063–2071

    Article  CAS  PubMed  Google Scholar 

  19. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bacher S, Cipriani A, Geddes JR, Salanti G, Davis JM (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174(10):927–942

    Article  PubMed  Google Scholar 

  20. Leucht S, Hierl S, Kissling W, Dold M, Davis JM (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 200(2):97–106

    Article  PubMed  Google Scholar 

  21. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6):195–235

    Article  PubMed  Google Scholar 

  22. Grunder G (2017) Editorial to consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry 51(1-02):5–6

    PubMed  Google Scholar 

  23. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mossner R, Muller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2017) Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1-02):9–62

    PubMed  Google Scholar 

  24. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research T (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71–93

    Article  PubMed  Google Scholar 

  25. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ, World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for S (2012) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13(5):318–378

    Article  PubMed  Google Scholar 

  26. NICE TNIfHaCE (2014) Psychosis and schizophrenia in adults: prevention and management

    Google Scholar 

  27. SIGN SIGN (2013) SIGN 131 • Management of schizophrenia • A national clinical guideline

    Google Scholar 

  28. Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167(6):686–693

    Article  PubMed  Google Scholar 

  29. Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, Liu TQ, Wang GH, Weng SM, Zhang HY, Chen DF, Tang WK, Ungvari GS, Risperidone Maintenance Treatment in Schizophrenia i (2010) Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry 167(6):676–685

    Article  PubMed  Google Scholar 

  30. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU (2013) Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry 26(2):219–230

    Article  PubMed  Google Scholar 

  31. Kuo CJ, Yang SY, Liao YT, Chen WJ, Lee WC, Shau WY, Chang YT, Tsai SY, Chen CC (2013) Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 39(3):648–657

    Article  PubMed  Google Scholar 

  32. Leucht S, Davis JM (2017) Do antipsychotic drugs lose their efficacy for relapse prevention over time? Br J Psychiatry 211(3):127–129

    Article  PubMed  Google Scholar 

  33. Sampson S, Mansour M, Maayan N, Soares-Weiser K, Adams CE (2013) Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev 7:CD006196

    Google Scholar 

  34. De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J (2015) The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs 29(8):637–658

    Article  CAS  PubMed  Google Scholar 

  35. Takeuchi H, Thiyanavadivel S, Agid O, Remington G (2018) Rapid vs. slow antipsychotic initiation in schizophrenia: a systematic review and meta-analysis. Schizophr Res 193:29–36

    Article  PubMed  Google Scholar 

  36. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D (2007) Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 68(5):654–661

    Article  PubMed  Google Scholar 

  37. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70(9):913–920

    Article  PubMed  Google Scholar 

  38. Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, Tso S, Pang EP, Chan KT, Wong YC, Mo FY, Chan KP, Yao TJ, Hung SF, Honer WG (2010) Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 341:c4024

    Article  PubMed  PubMed Central  Google Scholar 

  39. Hui CLM, Honer WG, Lee EHM, Chang WC, Chan SKW, Chen ESM, Pang EPF, Lui SSY, Chung DWS, Yeung WS, Ng RMK, Lo WTL, Jones PB, Sham P, Chen EYH (2018) Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 5(5):432–442

    Article  PubMed  Google Scholar 

  40. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, Riedel M, Klingberg S, Kopcke W, Ohmann C, Moller HJ, German Study Group on First-Episode S (2011) Relapse prevention in first-episode schizophrenia – maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 72(2):205–218

    Article  PubMed  Google Scholar 

  41. Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M, Muller P, Muller-Spahn F, Tegeler J (2002) First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 53(1–2):145–159

    Article  PubMed  Google Scholar 

  42. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE, group Es (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618):1085–1097

    Article  CAS  PubMed  Google Scholar 

  43. Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, Iyo M (2015) Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res 227(2–3):278–282

    Article  CAS  PubMed  Google Scholar 

  44. Yin J, Barr AM, Ramos-Miguel A, Procyshyn RM (2017) Antipsychotic induced dopamine supersensitivity psychosis: a comprehensive review. Curr Neuropharmacol 15(1):174–183

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Moncrieff J (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114(1):3–13

    Article  CAS  PubMed  Google Scholar 

  46. Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, Di Forti M, Taylor D (2016) Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 209(5):361–365

    Article  PubMed  Google Scholar 

  47. Cerovecki A, Musil R, Klimke A, Seemuller F, Haen E, Schennach R, Kuhn KU, Volz HP, Riedel M (2013) Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 27(7):545–572

    Article  CAS  PubMed  Google Scholar 

  48. Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M (2017) Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom 86(4):189–219

    Article  PubMed  Google Scholar 

  49. Tranter R, Healy D (1998) Neuroleptic discontinuation syndromes. J Psychopharmacol 12(4):401–406

    Article  CAS  PubMed  Google Scholar 

  50. Gupta S, Cahill JD (2016) A prescription for „deprescribing“ in psychiatry. Psychiatr Serv 67(8):904–907

    Article  PubMed  Google Scholar 

  51. Schlimme JE, Scholz T, Seroka R (2018) Medikamentenreduktion und Genesung von Psychosen. Psychiatrie, Köln

    Google Scholar 

  52. Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC (2011) Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull 37(4):788–799

    Article  PubMed  Google Scholar 

  53. Leucht S (2014) Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry 75(Suppl 1):8–14

    Article  PubMed  Google Scholar 

  54. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276

    Article  CAS  PubMed  Google Scholar 

  55. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville

    Google Scholar 

  56. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162(3):441–449

    Article  PubMed  Google Scholar 

  57. Guy W BR (1976) In: Chase C (Hrsg) CGI: clinical global impressions. National Institute of Mental Health

    Google Scholar 

  58. Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 4(7):28–37

    PubMed  PubMed Central  Google Scholar 

  59. Agid O, Kapur S, Arenovich T, Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60(12):1228–1235

    Article  CAS  PubMed  Google Scholar 

  60. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005) Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57(12):1543–1549

    Article  CAS  PubMed  Google Scholar 

  61. Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Moller HJ, Pelayo-Teran JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172(7):617–629

    Article  PubMed  Google Scholar 

  62. Leucht S, Zhao J (2014) Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. J Psychopharmacol 28(4):387–394

    Article  PubMed  Google Scholar 

  63. Kane JM, Leucht S, Carpenter D, Docherty JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic D (2003) The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64(Suppl 12):5–19

    PubMed  Google Scholar 

  64. Brooks GW (1959) Withdrawal from neuroleptic drugs. Am J Psychiatry 115(10):931–932

    Article  CAS  PubMed  Google Scholar 

  65. Wyatt RJ (1995) Risks of withdrawing antipsychotic medications. Arch Gen Psychiatry 52(3):205–208

    Article  CAS  PubMed  Google Scholar 

  66. Luchins DJ, Freed WJ, Wyatt RJ (1980) The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 137(11):1395–1398

    Article  CAS  PubMed  Google Scholar 

  67. Keks NA, Copolov DI, Burrpws D (1995) Discontinuing antipsychotic therapy: a practical guide. CNS Drugs 4:351–356

    Article  Google Scholar 

  68. Barnes TR (2011) Schizophrenia Consensus Group of British Association for P. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25(5):567–620

    Article  CAS  PubMed  Google Scholar 

  69. Zhu Y, Krause M, Huhn M, Rothe P, Schneider-Thoma J, Chaimani A, Li C, Davis JM, Leucht S (2017) Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 4(9):694–705

    Article  PubMed  Google Scholar 

  70. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU (2013) Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 16(6):1205–1218

    Article  CAS  PubMed  Google Scholar 

  71. Zhu Y, Li C, Huhn M, Rothe P, Krause M, Bighelli I, Schneider-Thoma J, Leucht S (2017) How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 27(9):835–844

    Article  CAS  PubMed  Google Scholar 

  72. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41

    Article  CAS  PubMed  Google Scholar 

  73. Naber D, Lambert M (2009) The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 23(8):649–659

    PubMed  Google Scholar 

  74. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Clinical Antipsychotic Trials of Intervention Effectiveness I. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–1223

    Article  CAS  PubMed  Google Scholar 

  75. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63(10):1079–1087

    Article  CAS  PubMed  Google Scholar 

  76. Alvarez-Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF (2011) Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull 37(3):619–630

    Article  PubMed  Google Scholar 

  77. Rosen K, Garety P (2005) Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophr Bull 31(3):735–750

    Article  PubMed  Google Scholar 

  78. Shepherd M, Watt D, Falloon I, Smeeton N (1989) The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl 15:1–46

    Article  CAS  PubMed  Google Scholar 

  79. Mason P, Harrison G, Glazebrook C, Medley I, Croudace T (1996) The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISoS) coordinated by the World Health Organization. Br J Psychiatry 169(5):580–586

    Article  CAS  PubMed  Google Scholar 

  80. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R (1998) Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 24(1):75–85

    Article  CAS  PubMed  Google Scholar 

  81. Harrow M, Jobe TH (2013) Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull 39(5):962–965

    Article  PubMed  PubMed Central  Google Scholar 

  82. Kirkpatrick B, Alphs L, Buchanan RW (1992) The concept of supersensitivity psychosis. J Nerv Ment Dis 180(4):265–270

    Article  CAS  PubMed  Google Scholar 

  83. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, CorrellI CU (2013) Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics [Schizophrenia & Psychotic States 3213]. Mol Psychiatry 1:53–66

    Article  CAS  Google Scholar 

  84. Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, Furukawa TA, Baldessarini RJ, Lim BP, Sim K (2016) Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open 2(1):59–66

    Article  PubMed  PubMed Central  Google Scholar 

  85. Tiihonen J, Tanskanen A, Taipale H (2018) 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. appiajp201817091001

    Google Scholar 

  86. Chouinard G, Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137(1):16–21

    Article  CAS  PubMed  Google Scholar 

  87. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric A, Steering Committee on Practice G (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1–56

    PubMed  Google Scholar 

  88. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ (2013) Schizophrenia WTfoTGf. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14(1):2–44

    Article  PubMed  Google Scholar 

  89. Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 50(5):410–472

    Article  PubMed  Google Scholar 

  90. Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G (2017) One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry 211(3):137–143

    Article  PubMed  Google Scholar 

  91. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56(3):241–247

    Article  CAS  PubMed  Google Scholar 

  92. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40(1):192–213

    Article  PubMed  Google Scholar 

  93. Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C (2017) Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res 183:10–21

    Article  PubMed  Google Scholar 

  94. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S (2011) Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127(1–3):83–92

    Article  PubMed  Google Scholar 

  95. Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ (2013) Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74(6):568–575

    Article  CAS  PubMed  Google Scholar 

  96. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU (2013) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74(10):957–965

    Article  PubMed  Google Scholar 

  97. Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtala J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry 74(7):686–693

    Article  PubMed  PubMed Central  Google Scholar 

  98. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168(6):603–609

    Article  PubMed  Google Scholar 

  99. Miyamoto S, Wolfgang Fleischhacker W (2017) The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psychiatry 4(2):117–126

    Article  PubMed  PubMed Central  Google Scholar 

  100. Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH (2015) Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry 72(8):822–829

    Article  PubMed  PubMed Central  Google Scholar 

  101. Carpenter WT Jr, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11(3):440–452

    Article  PubMed  Google Scholar 

  102. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (2015) Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 41(4):892–899

    Article  PubMed  Google Scholar 

  103. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166(1):68–72

    Article  CAS  PubMed  Google Scholar 

  104. Danion JM, Rein W, Fleurot O (1999) Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 156(4):610–616

    CAS  PubMed  Google Scholar 

  105. Lecrubier Y, Bouhassira M, Olivier V, Lancrenon S, Crawdord AM (1999) Olanzapine versus amisulpride and placebo in the treatment of negative symptoms and deficit states of chronic schizophrenia (Abstract). Eur Neuropsychopharmacol 9(Suppl 5):288

    Article  Google Scholar 

  106. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170:18–22

    Article  CAS  PubMed  Google Scholar 

  107. Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152(1):130–134

    Article  CAS  PubMed  Google Scholar 

  108. Möller HJ, Riedel M, Muller N, Fischer W, Kohnen R (2004) Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry 37(6):270–278

    Article  CAS  PubMed  Google Scholar 

  109. Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S (2006) The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 114(5):319–327

    Article  CAS  PubMed  Google Scholar 

  110. Olie JP, Spina E, Murray S, Yang R (2006) Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol 21(3):143–151

    Article  PubMed  Google Scholar 

  111. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, Leucht S (2018) Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 268(7):625–639

    Article  PubMed  Google Scholar 

  112. Nemeth G, Laszlovszky I, Czobor P, Szalai E, Szatmari B, Harsanyi J, Barabassy A, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW (2017) Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet 389(10074):1103–1113

    Article  CAS  PubMed  Google Scholar 

  113. GBA (2018) Nutzenbewertungsverfahren zum Wirkstoff Cariprazin. https://www.g-ba.de/informationen/nutzenbewertung/360/

  114. Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR (2017) Bitopertin in negative symptoms of schizophrenia-results from the phase III flashlyte and daylyte studies. Biol Psychiatry 82(1):8–16

    Article  CAS  PubMed  Google Scholar 

  115. Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, Engel RR, Leucht S (2016) Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 173(9):876–886

    Article  PubMed  Google Scholar 

  116. Katschnig H (2006) Quality of life in mental disorders: challenges for research and clinical practice. World Psychiatry 5(3):139–145

    PubMed  PubMed Central  Google Scholar 

  117. Petkari E, Pietschnig J (2015) Associations of quality of life with service satisfaction in psychotic patients: a meta-analysis. PLoS ONE 10(8):e0135267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Grunder G, Heinze M, Cordes J, Muhlbauer B, Juckel G, Schulz C, Ruther E, Timm J, Ne SSG (2016) Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry 3(8):717–729

    Article  PubMed  Google Scholar 

  119. Hamer S, Haddad PM (2007) Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl 50:s64–s70

    Article  PubMed  Google Scholar 

  120. Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin SG (2015) Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res 168(1–2):498–504

    Article  PubMed  Google Scholar 

  121. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA, Investigators C (2007) Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 164(3):428–436

    Article  PubMed  Google Scholar 

  122. Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G (2014) Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. Eur Neuropsychopharmacol 24(7):1078–1085

    Article  CAS  PubMed  Google Scholar 

  123. Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L (2014) Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophr Res 158(1–3):156–162

    Article  PubMed  Google Scholar 

  124. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Kahn RS (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166(6):675–682

    Article  PubMed  Google Scholar 

  125. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, Investigators C, Neurocognitive Working G (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64(6):633–647

    Article  CAS  PubMed  Google Scholar 

  126. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89(1–3):211–224

    Article  PubMed  Google Scholar 

  127. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8(3):457–472

    Article  CAS  PubMed  Google Scholar 

  128. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25(2):201–222

    Article  CAS  PubMed  Google Scholar 

  129. Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55(10):1013–1022

    Article  CAS  PubMed  Google Scholar 

  130. Desamericq G, Schurhoff F, Meary A, Szoke A, Macquin-Mavier I, Bachoud-Levi AC, Maison P (2014) Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol 70(2):127–134

    Article  CAS  PubMed  Google Scholar 

  131. Nielsen RE, Levander S, Kjaersdam Telleus G, Jensen SO, Ostergaard Christensen T, Leucht S (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia – a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 131(3):185–196

    Article  CAS  PubMed  Google Scholar 

  132. Singh J, Kour K, Jayaram MB (2012) Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev 1:CD007967

    PubMed  Google Scholar 

  133. Meltzer HY (1997) Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opin 14(1):1–20

    Article  CAS  PubMed  Google Scholar 

  134. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G (1994) One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 151(10):1409–1416

    Article  CAS  PubMed  Google Scholar 

  135. Helgason L (1990) Twenty years’ follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr Scand 81(3):231–235

    Article  CAS  PubMed  Google Scholar 

  136. Leucht S (2016) Behandlungsresistenz. In: Falkai P (Hrsg) Praxishandbuch Schizophrenie, Bd 1. Elsevier, S 162–163

    Google Scholar 

  137. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthoj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Moller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Ucok A, Umbricht D, Walters JT, Kane J, Correll CU (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174(3):216–229

    Article  PubMed  Google Scholar 

  138. Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, Leucht S (2016) Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 73(3):199–210

    Article  PubMed  Google Scholar 

  139. Siskind D, McCartney L, Goldschlager R, Kisely S (2016) Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209(5):385–392

    Article  PubMed  Google Scholar 

  140. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, Investigators C (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163(4):600–610

    Article  PubMed  Google Scholar 

  141. Essock SM, Frisman LK, Covell NH, Hargreaves WA (2000) Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 57(10):987–994

    Article  CAS  PubMed  Google Scholar 

  142. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB (2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32(4):715–723

    Article  PubMed  PubMed Central  Google Scholar 

  143. Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M (2016) Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 173(2):166–173

    Article  PubMed  Google Scholar 

  144. Nielsen J, Nielsen RE, Correll CU (2012) Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol 32(5):678–683

    Article  CAS  PubMed  Google Scholar 

  145. Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, Kane JM (2002) Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 63(5):420–424

    Article  PubMed  Google Scholar 

  146. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D (2012) Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 201(6):481–485

    Article  PubMed  Google Scholar 

  147. Taylor DM, Young C, Paton C (2003) Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 64(1):30–34

    Article  PubMed  Google Scholar 

  148. Warnez S, Alessi-Severini S (2014) Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 14:102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Gee S, Vergunst F, Howes O, Taylor D (2014) Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 130(1):16–24

    Article  CAS  PubMed  Google Scholar 

  150. Cohen D (2014) Prescribers fear as a major side-effect of clozapine. Acta Psychiatr Scand 130(2):154–155

    Article  CAS  PubMed  Google Scholar 

  151. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yagcioglu AE, Small JG (2008) A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 69(2):274–285

    Article  CAS  PubMed  Google Scholar 

  152. Dold M, Fugger G, Aigner M, Lanzenberger R, Kasper S (2015) Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 166(1–3):187–193

    Article  PubMed  Google Scholar 

  153. Sneider B, Pristed SG, Correll CU, Nielsen J (2015) Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: a nation-wide pharmacoepidemiological study. Eur Neuropsychopharmacol 25(10):1669–1676

    Article  CAS  PubMed  Google Scholar 

  154. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138(1):18–28

    Article  PubMed  PubMed Central  Google Scholar 

  155. Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU (2017) Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 16(1):77–89

    Article  PubMed  PubMed Central  Google Scholar 

  156. Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S (2017) Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74(7):675–684

    Article  PubMed  PubMed Central  Google Scholar 

  157. Wang Y, Xia J, Helfer B, Li C, Leucht S (2016) Valproate for schizophrenia. Cochrane Database Syst Rev 11:CD004028

    PubMed  Google Scholar 

  158. Leucht S, Helfer B, Dold M, Kissling W, McGrath J (2014) Carbamazepine for schizophrenia. Cochrane Database Syst Rev 5:CD001258

    Google Scholar 

  159. Leucht S, Helfer B, Dold M, Kissling W, McGrath JJ (2015) Lithium for schizophrenia. Cochrane Database Syst Rev 10:CD003834

    Google Scholar 

  160. Zheng W, Xiang YT, Xiang YQ, Li XB, Ungvari GS, Chiu HF, Correll CU (2016) Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand 134(5):385–398

    Article  CAS  PubMed  Google Scholar 

  161. Taylor DM, Smith L (2009) Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 119(6):419–425

    Article  CAS  PubMed  Google Scholar 

  162. Barnes T, Leeseon V, Paton C, Marston L, Osborn D, Kumar R, Keown P, Zafar R, Iqbal K, Singh V, Friedrich P, Fitzgerald Z, Bagalkote H, Haddad P, Husni M, Kumar R (2017) Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: the amicus study. Schizophr Bull 43(Suppl 1):164. (Abstracts for the 16th International Congress on Schizophrenia Research)

    Article  Google Scholar 

  163. Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115–1125

    Article  CAS  PubMed  Google Scholar 

  164. Sommer IE, Begemann MJ, Temmerman A, Leucht S (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38(5):1003–1011

    Article  PubMed  Google Scholar 

  165. Veerman SR, Schulte PF, Begemann MJ, de Haan L (2014) Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry 47(7):231–238

    Article  CAS  PubMed  Google Scholar 

  166. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA (2005) Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162(1):130–136

    Article  PubMed  Google Scholar 

  167. Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW (2010) Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 35(11):2274–2283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC (2007) Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 92(1–3):90–94

    Article  PubMed  Google Scholar 

  169. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, Ertugrul A, Jayathilake K, Gogus A, Tunca Z, Meltzer HY (2005) A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66(1):63–72

    Article  PubMed  Google Scholar 

  170. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R, Clozapine, Risperidone Enhancement Study G (2006) Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354(5):472–482

    Article  CAS  PubMed  Google Scholar 

  171. Bundesärztekammer (2003) Stellungnahme zur Elektrokrampftherapie (EKT) als psychiatrische Behandlungsmaßnahme. Dtsch Ärztebl (3)

    Google Scholar 

  172. DGPPN (2012) Elektrokonvulsionstherapie: Psychiatrische Fachgesellschaften aus vier Ländern empfehlen einen rechtzeitigen und adäquaten Einsatz. Nervenarzt 83(7):919–925

    Article  Google Scholar 

  173. Tharyan P, Adams CE (2005) Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2:CD000076

    Google Scholar 

  174. Leroy A, Naudet F, Vaiva G, Francis A, Thomas P, Amad A (2017) Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 268(7):675–687

    Article  PubMed  Google Scholar 

  175. Zheng W, Cao XL, Ungvari GS, Xiang YQ, Guo T, Liu ZR, Wang YY, Forester BP, Seiner SJ, Xiang YT (2016) Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: meta-analysis of randomized controlled trials. PLoS ONE 11(6):e0156510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, Kane JM, Sanghani S, Goldberg TE, John M, Mendelowitz A (2015) Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 172(1):52–58

    Article  PubMed  Google Scholar 

  177. Lin HT, Liu SK, Hsieh MH, Chien YL, Chen IM, Liao SC, Tsai HJ, Wu CS (2017) Impacts of electroconvulsive therapy on 1-year outcomes in patients with schizophrenia: a controlled, population-based mirror-image study. Schizophr Bull 44(4):798–806

    Article  PubMed Central  Google Scholar 

  178. Grover S, Chakrabarti S, Hazari N, Avasthi A (2017) Effectiveness of electroconvulsive therapy in patients with treatment resistant schizophrenia: a retrospective study. Psychiatry Res 249:349–353

    Article  PubMed  Google Scholar 

  179. Rosa MA, Lisanby SH (2012) Somatic treatments for mood disorders. Neuropsychopharmacology 37(1):102–116

    Article  CAS  PubMed  Google Scholar 

  180. Lally J, Tully J, Robertson D, Stubbs B, Gaughran F, MacCabe JH (2016) Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 171(1–3):215–224

    Article  PubMed  Google Scholar 

  181. Chanpattana W, Chakrabhand ML, Sackeim HA, Kitaroonchai W, Kongsakon R, Techakasem P, Buppanharun W, Tuntirungsee Y, Kirdcharoen N (1999) Continuation ECT in treatment-resistant schizophrenia: a controlled study. J ECT 15(3):178–192

    Article  CAS  PubMed  Google Scholar 

  182. Yang Y, Cheng X, Xu Q, Li R, Liu Z, Wang L, Zhang Y, Ren G, Liu J (2016) The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. Arq Neuropsiquiatr 74(10):823–828

    Article  PubMed  Google Scholar 

  183. Ward HB, Szabo ST, Rakesh G (2018) Maintenance ECT in schizophrenia: a systematic review. Psychiatry Res 264:131–142

    Article  PubMed  Google Scholar 

  184. NICE TNIfHaCE (2004) Depression: Management of depression in primary and secondary care. Clinical Guideline 23. http://www.nice.org.uk/page.aspx?o=235213

  185. Canadian Psychiatric A, Canadian Network for M, Anxiety T (2001) Clinical guidelines for the treatment of depressive disorders. Can J Psychiatr 46(Suppl 1):5S–90S

    Google Scholar 

  186. Lisanby SH, Maddox JH, Prudic J, Devanand DP, Sackeim HA (2000) The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry 57(6):581–590

    Article  CAS  PubMed  Google Scholar 

  187. Schizophrenia Working Group of the Psychiatric Genomics C (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421–427

    Article  CAS  Google Scholar 

  188. Devanand DP, Dwork AJ, Hutchinson ER, Bolwig TG, Sackeim HA (1994) Does ECT alter brain structure? Am J Psychiatry 151(7):957–970

    Article  CAS  PubMed  Google Scholar 

  189. Ziegelmayer C, Hajak G, Bauer A, Held M, Rupprecht R, Trapp W (2017) Cognitive performance under electroconvulsive therapy (ECT) in ECT-naive treatment-resistant patients with major depressive disorder. J ECT 33(2):104–110

    Article  PubMed  Google Scholar 

  190. Bergfeld IO, Mantione M, Hoogendoorn MLC, Horst F, Notten P, Schuurman PR, Denys D (2017) Episodic memory following deep brain stimulation of the ventral anterior limb of the internal capsule and electroconvulsive therapy. Brain Stimul 10(5):959–966

    Article  PubMed  Google Scholar 

  191. Tor PC, Ying J, Ho NF, Wang M, Martin D, Ang CP, Tan C, Yap LS, Lu VJM, Simpson B, Mok YM, Loo C (2017) Effectiveness of electroconvulsive therapy and associated cognitive change in schizophrenia: a naturalistic, comparative study of treating schizophrenia with electroconvulsive therapy. J ECT 33(4):272–277

    Article  PubMed  Google Scholar 

  192. Sanghani SN, Petrides G, Kellner CH (2018) Electroconvulsive therapy (ECT) in schizophrenia: a review of recent literature. Curr Opin Psychiatry 31(3):213–222

    Article  PubMed  Google Scholar 

  193. Aftab A, VanDercar A, Alkhachroum A, LaGrotta C, Gao K (2018) Nonconvulsive status epilepticus after electroconvulsive therapy: a review of literature. Psychosomatics 59(1):36–46

    Article  PubMed  Google Scholar 

  194. Zeiler FA, Matuszczak M, Teitelbaum J, Gillman LM, Kazina CJ (2016) Electroconvulsive therapy for refractory status epilepticus: a systematic review. Seizure 35:23–32

    Article  CAS  PubMed  Google Scholar 

  195. Hasan A, Wobrock T, Palm U, Strube W, Padberg F, Falkai P, Fallgatter A, Plewnia C (2015) Non-invasive brain stimulation for treatment of schizophrenic psychoses. Nervenarzt 86(12):1481–1491

    Article  CAS  PubMed  Google Scholar 

  196. Lefaucheur JP, Andre-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder D, Devanne H, Di Lazzaro V, Filipovic SR, Hummel FC, Jaaskelainen SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A, Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schonfeldt-Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J, Ziemann U, Paulus W, Garcia-Larrea L (2014) Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 125(11):2150–2206

    Article  PubMed  Google Scholar 

  197. He H, Lu J, Yang L, Zheng J, Gao F, Zhai Y, Feng J, Fan Y, Ma X (2017) Repetitive transcranial magnetic stimulation for treating the symptoms of schizophrenia: a PRISMA compliant meta-analysis. Clin Neurophysiol 128(5):716–724

    Article  PubMed  Google Scholar 

  198. Slotema CW, Blom JD, van Lutterveld R, Hoek HW, Sommer IE (2014) Review of the efficacy of transcranial magnetic stimulation for auditory verbal hallucinations. Biol Psychiatry 76(2):101–110

    Article  PubMed  Google Scholar 

  199. Shi C, Yu X, Cheung EF, Shum DH, Chan RC (2014) Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Res 215(3):505–513

    Article  PubMed  Google Scholar 

  200. Osoegawa C, Gomes JS, Grigolon RB, Brietzke E, Gadelha A, Lacerda ALT, Dias AM, Cordeiro Q, Laranjeira R, de Jesus D, Daskalakis ZJ, Brunelin J, Cordes J, Trevizol AP (2018) Non-invasive brain stimulation for negative symptoms in schizophrenia: an updated systematic review and meta-analysis. Schizophr Res:S0920-9964(18)30031-8. https://doi.org/10.1016/j.schres.2018.01.010. [Epub ahead of print]

  201. Wobrock T, Guse B, Cordes J, Wölwer W, Winterer G, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, Schneider-Axmann T, Falkai P, Hasan A (2015) Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biol Psychiatry 77(11):979–988

    Article  PubMed  Google Scholar 

  202. Hasan A, Wolff-Menzler C, Pfeiffer S, Falkai P, Weidinger E, Jobst A, Hoell I, Malchow B, Yeganeh-Doost P, Strube W, Quast S, Muller N, Wobrock T (2015) Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study. Eur Arch Psychiatry Clin Neurosci 265(7):589–600

    Article  PubMed  Google Scholar 

  203. Plewnia C, Zwissler B, Wasserka B, Fallgatter AJ, Klingberg S (2014) Treatment of auditory hallucinations with bilateral theta burst stimulation: a randomized controlled pilot trial. Brain Stimul 7(2):340–341

    Article  PubMed  Google Scholar 

  204. Koops S, van Dellen E, Schutte MJ, Nieuwdorp W, Neggers SF, Sommer IE (2016) Theta burst transcranial magnetic stimulation for auditory verbal hallucinations: negative findings from a double-blind-randomized trial. Schizophr Bull 42(1):250–257

    PubMed  Google Scholar 

  205. Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W (2017) Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol 128(1):56–92

    Article  PubMed  Google Scholar 

  206. Wolkowitz OM, Pickar D (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 148(6):714–726

    Article  CAS  PubMed  Google Scholar 

  207. Fontanella CA, Campo JV, Phillips GS, Hiance-Steelesmith DL, Sweeney HA, Tam K, Lehrer D, Klein R, Hurst M (2016) Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry 77(5):661–667

    Article  PubMed  Google Scholar 

  208. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 71(2):103–108

    Article  PubMed  Google Scholar 

  209. Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173(6):600–606

    Article  PubMed  Google Scholar 

  210. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69(5):476–483

    Article  CAS  PubMed  Google Scholar 

  211. Dold M, Li C, Gillies D, Leucht S (2013) Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23(9):1023–1033

    Article  CAS  PubMed  Google Scholar 

  212. Gillies D, Sampson S, Beck A, Rathbone J (2013) Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 9:CD003079

    PubMed  Google Scholar 

  213. Spina E, de Leon J (2014) Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 10(5):721–746

    Article  CAS  PubMed  Google Scholar 

  214. Ereshefsky L (1996) Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 57(Suppl 11):12–25

    CAS  PubMed  Google Scholar 

  215. Shek E, Bardhan S, Cheine MV, Ahonen J, Wahlbeck K (2010) Beta-blocker supplementation of standard drug treatment for schizophrenia. Schizophr Bull 36(6):1079–1080

    Article  PubMed  PubMed Central  Google Scholar 

  216. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, Davis JM, Leucht S (2012) Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 38(1):167–177

    Article  PubMed  Google Scholar 

  217. Goetz CG, Klawans HL (1981) Drug-induced extrapyramidal disorders – a neuropsychiatric interface. J Clin Psychopharmacol 1(5):297–303

    Article  CAS  PubMed  Google Scholar 

  218. Rupniak NM, Jenner P, Marsden CD (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology 88(4):403–419

    Article  CAS  PubMed  Google Scholar 

  219. Braude WM, Barnes TR, Gore SM (1983) Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 143:139–150

    Article  CAS  PubMed  Google Scholar 

  220. Grebb JA (1995) Medication induced movement disorders. In: Kaplan HI, Sadock BJ (Hrsg) Comprehensive textbook of psychiatry. Williams & Wilkins, New York

    Google Scholar 

  221. Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA (2015) The clinical challenges of akathisia. CNS Spectr 20(Suppl 1):1–14; quiz 5-6

    Article  PubMed  Google Scholar 

  222. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ, Schizophrenia WTFoTGf (2015) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: update 2015 Management of special circumstances: depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16(3):142–170

    Article  PubMed  Google Scholar 

  223. Kane JM, Woerner M, Lieberman J (1988) Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8(4 Suppl):52S–56S

    CAS  PubMed  Google Scholar 

  224. Morgenstern H, Glazer WM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 50(9):723–733

    Article  CAS  PubMed  Google Scholar 

  225. Glazer WM (2000) Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61(Suppl 4):15–20

    PubMed  Google Scholar 

  226. Glazer WM, Morgenstern H, Doucette JT (1993) Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 54(4):133–139

    CAS  PubMed  Google Scholar 

  227. Correll CU, Schenk EM (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21(2):151–156

    Article  PubMed  Google Scholar 

  228. Carbon M, Hsieh CH, Kane JM, Correll CU (2017) Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 78(3):e264–ee78

    Article  PubMed  Google Scholar 

  229. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 71(4):463–474

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  230. Fenton WS (2000) Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 61(Suppl 4):10–14

    PubMed  Google Scholar 

  231. Merrill RM, Lyon JL, Matiaco PM (2013) Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry 13:152

    Article  PubMed  PubMed Central  Google Scholar 

  232. Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Chiliza B, Fincham D (2011) Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry 26(5):293–296

    Article  CAS  PubMed  Google Scholar 

  233. Yassa R (1989) Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand 80(1):64–67

    Article  CAS  PubMed  Google Scholar 

  234. Pileggi DJ, Cook AM (2016) Neuroleptic Malignant Syndrome. Ann Pharmacother 50(11):973–981

    Article  CAS  PubMed  Google Scholar 

  235. Nagel M, Freisberg S, Junghanns K, Moll CK, Willenborg B (2015) [The Neuroleptic Malignant Syndrome]. Fortschr Neurol Psychiatr 83(7):373–380

    Google Scholar 

  236. Gelenberg AJ, Bellinghausen B, Wojcik JD, Falk WE, Sachs GS (1988) A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 145(4):517–518

    Article  CAS  PubMed  Google Scholar 

  237. Spivak B, Maline DI, Kozyrev VN, Mester R, Neduva SA, Ravilov RS, Weizman A (2000) Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry 15(5):330–333

    Article  CAS  PubMed  Google Scholar 

  238. Strawn JR, Keck PE Jr, Caroff SN (2007) Neuroleptic malignant syndrome. Am J Psychiatry 164(6):870–876

    Article  PubMed  Google Scholar 

  239. Alper K, Schwartz KA, Kolts RL, Khan A (2007) Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62(4):345–354

    Article  PubMed  Google Scholar 

  240. Devinsky O, Honigfeld G, Patin J (1991) Clozapine-related seizures. Neurology 41(3):369–371

    Article  CAS  PubMed  Google Scholar 

  241. Holt RI (2008) Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. J Psychopharmacol 22(2 Suppl):28–37

    Article  PubMed  Google Scholar 

  242. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3):519–526

    Article  CAS  PubMed  Google Scholar 

  243. Bora E, Akdede BB, Alptekin K (2017) The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med 47(6):1030–1040

    Article  CAS  PubMed  Google Scholar 

  244. Musil R, Obermeier M, Russ P, Hamerle M (2015) Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 14(1):73–96

    Article  CAS  PubMed  Google Scholar 

  245. Lipkovich I, Jacobson JG, Caldwell C, Hoffmann VP, Kryzhanovskaya L, Beasley CM (2009) Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials. Psychopharmacol Bull 42(4):23–39

    PubMed  Google Scholar 

  246. Haddad P (2005) Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 19(6 Suppl):16–27

    Article  PubMed  Google Scholar 

  247. Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74(3):261–269

    Article  PubMed  PubMed Central  Google Scholar 

  248. Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, Fernandez-Egea E, Miller B, Arroyo MB, Kirkpatrick B (2017) Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naive patients with nonaffective psychosis. Schizophr Res 179:57–63

    Article  PubMed  Google Scholar 

  249. Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS (2015) Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72(12):1172–1181

    Article  PubMed  Google Scholar 

  250. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10(1):52–77

    Article  Google Scholar 

  251. Jafari S, Fernandez-Enright F, Huang XF (2012) Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. J Neurochem 120(3):371–384

    Article  CAS  PubMed  Google Scholar 

  252. American Diabetes A, American Psychiatric A, American Association of Clinical E, North American Association for the Study of O (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65(2):267–272

    Article  Google Scholar 

  253. Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T (2017) Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 40(9):771–781

    Article  CAS  PubMed  Google Scholar 

  254. Glassman AH, Bigger JT Jr (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158(11):1774–1782

    Article  CAS  PubMed  Google Scholar 

  255. Ronaldson KJ, Fitzgerald PB, McNeil JJ (2015) Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 132(4):231–240

    Article  CAS  PubMed  Google Scholar 

  256. Curto M, Girardi N, Lionetto L, Ciavarella GM, Ferracuti S, Baldessarini RJ (2016) Systematic review of clozapine cardiotoxicity. Curr Psychiatry Rep 18(7):68

    Article  PubMed  Google Scholar 

  257. De Hert M, Hudyana H, Dockx L, Bernagie C, Sweers K, Tack J, Leucht S, Peuskens J (2011) Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry 26(1):34–44

    Article  PubMed  Google Scholar 

  258. Every-Palmer S, Newton-Howes G, Clarke MJ (2017) Pharmacological treatment for antipsychotic-related constipation. Cochrane Database Syst Rev 1:CD011128

    PubMed  Google Scholar 

  259. Every-Palmer S, Ellis PM (2017) Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal ‚slow gut‘ reactions, and comparison with international drug safety advice. CNS Drugs 31(8):699–709

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  260. Hung GC, Liu HC, Yang SY, Pan CH, Liao YT, Chen CC, Kuo CJ (2016) Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study. J Clin Psychiatry 77(1):60–66

    Article  PubMed  Google Scholar 

  261. Gambassi G, Sultana J, Trifiro G (2015) Antipsychotic use in elderly patients and the risk of pneumonia. Expert Opin Drug Saf 14(1):1–6

    Article  CAS  PubMed  Google Scholar 

  262. Chen YH, Lin HC, Lin HC (2011) Poor clinical outcomes among pneumonia patients with schizophrenia. Schizophr Bull 37(5):1088–1094

    Article  PubMed  Google Scholar 

  263. Winkelman JW (2001) Schizophrenia, obesity, and obstructive sleep apnea. J Clin Psychiatry 62(1):8–11

    Article  CAS  PubMed  Google Scholar 

  264. Laoutidis ZG, Kioulos KT (2014) Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice. Psychopharmacology 231(22):4255–4270

    Article  CAS  PubMed  Google Scholar 

  265. Voros V, Osvath P, Fekete S, Tenyi T (2008) Elevated serum creatine kinase levels in psychiatric practice: differential diagnosis and clinical significance: a brief, practical guideline for clinicians. Int J Psychiatry Clin Pract 12(2):147–150

    Article  CAS  PubMed  Google Scholar 

  266. Ogino S, Miyamoto S, Miyake N, Yamaguchi N (2014) Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci 68(1):37–49

    Article  CAS  PubMed  Google Scholar 

  267. Haag A, Hermsen A, Knake S, Rosenow F (2012) Kognitive Nebenwirkungen neuer Antikonvulsiva. Z Epileptol 25:252–258

    Article  Google Scholar 

  268. Stranks EK, Crowe SF (2014) The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol 36(7):691–700

    Article  PubMed  Google Scholar 

  269. Reilly JL, Harris MS, Khine TT, Keshavan MS, Sweeney JA (2007) Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol Psychiatry 62(7):818–821

    Article  CAS  PubMed  Google Scholar 

  270. Reilly JL, Harris MS, Keshavan MS, Sweeney JA (2006) Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry 63(11):1189–1197

    Article  CAS  PubMed  Google Scholar 

  271. Vita A, De Peri L, Deste G, Barlati S, Sacchetti E (2015) The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biol Psychiatry 78(6):403–412

    Article  CAS  PubMed  Google Scholar 

  272. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS (2013) Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 39(5):1129–1138

    Article  PubMed  Google Scholar 

  273. van TGM E, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, Pearlson GD, Yao N, Fukunaga M, Hashimoto R, Okada N, Yamamori H, Bustillo JR, Clark VP, Agartz I, Mueller BA, Cahn W, de Zwarte SMC, Hulshoff Pol HE, Kahn RS, Ophoff RA, van Haren NEM, Andreassen OA, Dale AM, Doan NT, Gurholt TP, Hartberg CB, Haukvik UK, Jorgensen KN, Lagerberg TV, Melle I, Westlye LT, Gruber O, Kraemer B, Richter A, Zilles D, Calhoun VD, Crespo-Facorro B, Roiz-Santianez R, Tordesillas-Gutierrez D, Loughland C, Carr VJ, Catts S, Cropley VL, Fullerton JM, Green MJ, Henskens FA, Jablensky A, Lenroot RK, Mowry BJ, Michie PT, Pantelis C, Quide Y, Schall U, Scott RJ, Cairns MJ, Seal M, Tooney PA, Rasser PE, Cooper G, Shannon Weickert C, Weickert TW, Morris DW, Hong E, Kochunov P, Beard LM, Gur RE, Gur RC, Satterthwaite TD, Wolf DH, Belger A, Brown GG, Ford JM, Macciardi F, Mathalon DH, O’Leary DS, Potkin SG, Preda A, Voyvodic J, Lim KO, McEwen S, Yang F, Tan Y, Tan S, Wang Z, Fan F, Chen J, Xiang H, Tang S, Guo H, Wan P, Wei D, Bockholt HJ, Ehrlich S, Wolthusen RPF, King MD, Shoemaker JM, Sponheim SR, De Haan L, Koenders L, Machielsen MW, van Amelsvoort T, Veltman DJ, Assogna F, Banaj N, de Rossi P, Iorio M, Piras F, Spalletta G, McKenna PJ, Pomarol-Clotet E, Salvador R, Corvin A, Donohoe G, Kelly S, Whelan CD, Dickie EW, Rotenberg D, Voineskos AN, Ciufolini S, Radua J, Dazzan P, Murray R, Reis Marques T, Simmons A, Borgwardt S, Egloff L, Harrisberger F, Riecher-Rossler A, Smieskova R, Alpert KI, Wang L, Jonsson EG, Koops S, Sommer IEC, Bertolino A, Bonvino A, Di Giorgio A, Neilson E, Mayer AR, Stephen JM, Kwon JS, Yun JY, Cannon DM, McDonald C, Lebedeva I, Tomyshev AS, Akhadov T, Kaleda V, Fatouros-Bergman H, Flyckt L, Karolinska Schizophrenia P, Busatto GF, Rosa PGP, Serpa MH, Zanetti MV, Hoschl C, Skoch A, Spaniel F, Tomecek D, Hagenaars SP, McIntosh AM, Whalley HC, Lawrie SM, Knochel C, Oertel-Knochel V, Stablein M, Howells FM, Stein DJ, Temmingh HS, Uhlmann A, Lopez-Jaramillo C, Dima D, McMahon A, Faskowitz JI, Gutman BA, Jahanshad N, Thompson PM, Turner JA (2018) Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (enigma) consortium. Biol Psychiatry 84(9):644–654

    Article  Google Scholar 

  274. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S (2013) Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 37(8):1680–1691

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  275. Fusar-Poli P, Radua J, McGuire P, Borgwardt S (2012) Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr Bull 38(6):1297–1307

    Article  PubMed  Google Scholar 

  276. Weinberger DR, Wagner RL, Wyatt RJ (1983) Neuropathological studies of schizophrenia: a selective review. Schizophr Bull 9(2):193–212

    Article  CAS  PubMed  Google Scholar 

  277. Hirose S (2003) The causes of underdiagnosing akathisia. Schizophr Bull 29(3):547–558

    Article  PubMed  Google Scholar 

  278. Barnes TR (2003) The Barnes Akathisia Rating Scale – revisited. J Psychopharmacol 17(4):365–370

    Article  PubMed  Google Scholar 

  279. Poyurovsky M (2010) Acute antipsychotic-induced akathisia revisited. Br J Psychiatry 196(2):89–91

    Article  PubMed  Google Scholar 

  280. Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K (2004) Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 4:CD001946

    Google Scholar 

  281. Lima AR, Weiser KV, Bacaltchuk J, Barnes TR (2004) Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 1:CD003727

    Google Scholar 

  282. Praharaj SK, Kongasseri S, Behere RV, Sharma PS (2015) Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Therap Adv Psychopharmacol 5(5):307–313

    Article  CAS  Google Scholar 

  283. Melamed E, Achiron A, Shapira A, Davidovicz S (1991) Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 14(3):273–278

    Article  CAS  PubMed  Google Scholar 

  284. Soares-Weiser K, Rathbone J (2006) Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 1:CD000459

    Google Scholar 

  285. van Harten PN, Kahn RS (1999) Tardive dystonia. Schizophr Bull 25(4):741–748

    Article  PubMed  Google Scholar 

  286. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2004) A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65(5):696–701

    Article  CAS  PubMed  Google Scholar 

  287. Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, Harricharan R (2008) Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 28(1):69–73

    Article  CAS  PubMed  Google Scholar 

  288. Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H (2004) Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuro-Psychopharmacol Biol Psychiatry 28(6):985–996

    Article  CAS  Google Scholar 

  289. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J (1991) The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503–510

    Article  CAS  PubMed  Google Scholar 

  290. Louza MR, Bassitt DP (2005) Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years’ follow-up. J Clin Psychopharmacol 25(2):180–182

    Article  CAS  PubMed  Google Scholar 

  291. Essali A, Deirawan H, Soares-Weiser K, Adams CE (2011) Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 11:CD000206

    Google Scholar 

  292. El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K (2006) Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 1:CD000458

    Google Scholar 

  293. Alabed S, Latifeh Y, Mohammad HA, Rifai A (2011) Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 4:CD000203

    Google Scholar 

  294. Bhoopathi PS, Soares-Weiser K (2006) Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 3:CD000205

    Google Scholar 

  295. Soares KV, McGrath JJ (2000) Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2:CD000204

    Google Scholar 

  296. Leung JG, Breden EL (2011) Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 45(4):525–531

    Article  CAS  PubMed  Google Scholar 

  297. Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV (2017) Efficient trial design – FDA approval of valbenazine for tardive dyskinesia. N Engl J Med 376(26):2503–2506

    Article  PubMed  Google Scholar 

  298. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O’Brien CF (2017) KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 174(5):476–484

    Article  PubMed  Google Scholar 

  299. Adelufosi AO, Abayomi O, Ojo TM (2015) Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 4:CD010501

    Google Scholar 

  300. Soares-Weiser K, Maayan N, McGrath J (2011) Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2:CD000209

    Google Scholar 

  301. Hay DP, Hay L, Blackwell B, Spiro HR (1990) ECT and tardive dyskinesia. J Geriatr Psychiatry Neurol 3(2):106–109

    CAS  PubMed  Google Scholar 

  302. Ucok A, Ucok G (1996) Maintenance ECT in a patient with catatonic schizophrenia and tardive dyskinesia. Convuls Ther 12(2):108–112

    CAS  PubMed  Google Scholar 

  303. Sienaert P, Peuskens J (2005) Remission of tardive dystonia (blepharospasm) after electroconvulsive therapy in a patient with treatment-refractory schizophrenia. J ECT 21(2):132–134

    Article  PubMed  Google Scholar 

  304. Nobuhara K, Matsuda S, Okugawa G, Tamagaki C, Kinoshita T (2004) Successful electroconvulsive treatment of depression associated with a marked reduction in the symptoms of tardive dyskinesia. J ECT 20(4):262–263

    Article  PubMed  Google Scholar 

  305. McGrath JJ, Soares KV (2000) Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2:CD000208

    Google Scholar 

  306. Sobstyl M, Zabek M (2016) Deep brain stimulation for intractable tardive dystonia: literature overview. Neurol Neurochir Pol 50(2):114–122

    Article  PubMed  Google Scholar 

  307. Gruber D, Trottenberg T, Kivi A, Schoenecker T, Kopp UA, Hoffmann KT, Schneider GH, Kuhn AA, Kupsch A (2009) Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 73(1):53–58

    Article  CAS  PubMed  Google Scholar 

  308. Verdura Vizcaino EJ, Ballesteros Sanz D, Sanz-Fuentenebro J (2011) Electroconvulsive therapy as treatment for malignant neuroleptic syndrome. Rev Psiquiatr Salud Ment 4(3):169–176

    Article  PubMed  Google Scholar 

  309. Davis JM, Janicak PG, Sakkas P, Gilmore C, Wang Z (1991) Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther 7(2):111–120

    PubMed  Google Scholar 

  310. Reulbach U, Dutsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J, Bleich S (2007) Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 11(1):R4

    Article  PubMed  PubMed Central  Google Scholar 

  311. Kontaxakis VP, Christodoulou GN, Markidis MP, Havaki-Kontaxaki BJ (1988) Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam. Acta Psychiatr Scand 78(3):396–398

    Article  CAS  PubMed  Google Scholar 

  312. Woodbury MM, Woodbury MA (1992) Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 31(6):1161–1164

    Article  CAS  PubMed  Google Scholar 

  313. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24(6):412–424

    Article  PubMed  Google Scholar 

  314. Mukundan A, Faulkner G, Cohn T, Remington G (2010) Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 12:CD006629

    Google Scholar 

  315. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J (2009) Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 107(1):22–29

    Article  PubMed  Google Scholar 

  316. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD (2008) Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 193(2):101–107

    Article  PubMed  Google Scholar 

  317. Teasdale SB, Ward PB, Rosenbaum S, Samaras K, Stubbs B (2017) Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry 210(2):110–118

    Article  PubMed  Google Scholar 

  318. Rosenbaum S, Tiedemann A, Sherrington C, Curtis J, Ward PB (2014) Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiatry 75(9):964–974

    Article  PubMed  Google Scholar 

  319. Green CA, Yarborough BJ, Leo MC, Yarborough MT, Stumbo SP, Janoff SL, Perrin NA, Nichols GA, Stevens VJ (2015) The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 172(1):71–81

    Article  PubMed  Google Scholar 

  320. de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R (2016) Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 16(1):341

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  321. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H (2014) Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40(6):1385–1403

    Article  PubMed  PubMed Central  Google Scholar 

  322. Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S (2016) Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLoS ONE 11(6):e0156208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  323. Mahmood S, Booker I, Huang J, Coleman CI (2013) Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 33(1):90–94

    Article  CAS  PubMed  Google Scholar 

  324. Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, Correll C, Soares JC, Yang FD, Wang SL, Zhang XY (2015) Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 58:130–140

    Article  CAS  PubMed  Google Scholar 

  325. Correll CU (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47(1):9–20

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Medizinische Fakultät (federführend), Düsseldorf, Deutschland

    Prof. Dr. Wolfgang Gaebel

  2. Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, München, Deutschland

    Prof. Dr. Alkomiet Hasan & Prof. Dr. Peter Falkai

Authors
  1. Prof. Dr. Wolfgang Gaebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Alkomiet Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. Peter Falkai
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Medizinische Fakultät (federführend), Düsseldorf, Germany

    Wolfgang Gaebel

  2. Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, München, Germany

    Alkomiet Hasan

  3. Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, München, Germany

    Peter Falkai

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN)

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gaebel, W., Hasan, A., Falkai, P. (2019). Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a). In: Gaebel, W., Hasan, A., Falkai, P. (eds) S3-Leitlinie Schizophrenie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59380-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59380-6_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59379-0

  • Online ISBN: 978-3-662-59380-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation